Zhang Yan, Guo Tingting, Li Shurong, Ren Zehao, Gao Shan, Lu Hao, Ma Xuelan, Liu Donghui, Liu Yao, Kong Dexin, Qiu Yuling
Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, China.
Department of Otorhinolaryngology Head and Neck Surgery, Tianjin First Central Hospital, Tianjin, China.
Discov Oncol. 2023 May 31;14(1):84. doi: 10.1007/s12672-023-00688-1.
The present study aimed to explore the anticancer activity of hirsuteine (HST), an indole alkaloid from the traditional Chinese herbal medicine Uncaria rhynchophylla, against colorectal cancer (CRC) and the underlining mechanism.
MTT, colony formation, flow cytometry and MDC staining were conducted to confirm the antiproliferative effect of HST on human CRC cells harboring different p53 status. Protein expressions were evaluated by the Western blot analysis. p53 protein half-life and the interaction between p53 and MDM2 were investigated using cycloheximide (CHX)-chase assay and Co-immunoprecipitation (Co-IP), respectively. Transcriptional activity of p53 was examined by qRT-PCR and Chromatin immunoprecipitation (ChIP). Xenograft tumor in nude mice was created to evaluate in vivo anticancer effect of HST against CRC.
HST inhibited cell growth, arrested cell cycle and induced autophagy, showing efficient anticancer effects on CRC cells independent of p53 status. In HCT-8 cells, HST prolonged wtp53 half-life, and upregulated mRNA level of p21, suggesting that HST activated the p53 pathway through enhancement of wtp53 stability and transcriptional activity. Meanwhile in SW620 cells, HST induced MDM2-mediated proteasomal degradation of mutp53, increased the DNA-binding ability of mutp53 at the p21 promoter, and upregulated mRNA levels of p21 and MDM2, demonstrating the depletion of mutp53 and restoration of its wild-type-like properties by HST. p53 knockdown by siRNA significantly impaired the growth inhibition of HST on HCT-8 and SW620 cells. Moreover, HST showed anticancer effects in xenograft tumors, accompanied with an opposite regulation of wtp53 and mutp53 in mechanism.
This study revealed the anticancer efficacy of HST against CRC via opposite modulation of wtp53 and mutp53 , indicating the potential of HST to be a CRC drug candidate targeting p53 signaling.
本研究旨在探讨钩藤中吲哚生物碱毛钩藤碱(HST)对结直肠癌(CRC)的抗癌活性及其潜在机制。
采用MTT法、集落形成实验、流式细胞术和MDC染色,以确认HST对具有不同p53状态的人CRC细胞的抗增殖作用。通过蛋白质印迹分析评估蛋白质表达。分别使用环己酰亚胺(CHX)追踪实验和免疫共沉淀(Co-IP)研究p53蛋白半衰期以及p53与MDM2之间的相互作用。通过qRT-PCR和染色质免疫沉淀(ChIP)检测p53的转录活性。在裸鼠中建立异种移植瘤模型,以评估HST对CRC的体内抗癌效果。
HST抑制细胞生长、阻滞细胞周期并诱导自噬,对CRC细胞显示出有效的抗癌作用,且与p53状态无关。在HCT-8细胞中,HST延长了野生型p53(wtp53)的半衰期,并上调了p21的mRNA水平,表明HST通过增强wtp53的稳定性和转录活性激活了p53通路。同时,在SW620细胞中,HST诱导MDM2介导的突变型p53(mutp53)蛋白酶体降解,增加了mutp53在p21启动子处的DNA结合能力,并上调了p21和MDM2的mRNA水平,证明HST可使mutp53减少并恢复其野生型样特性。用siRNA敲低p53可显著削弱HST对HCT-8和SW620细胞的生长抑制作用。此外,HST在异种移植瘤中显示出抗癌作用,其机制伴随着对wtp53和mutp53的相反调节。
本研究揭示了HST通过对wtp53和mutp53的相反调节对CRC的抗癌功效,表明HST有潜力成为一种靶向p53信号通路的CRC候选药物。